Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Abstract Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission tomography (PET) may identify those pati...

Full description

Bibliographic Details
Main Authors:	E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse
Format:	Article
Language:	English
Published:	SpringerOpen 2020-08-01
Series:	EJNMMI Research
Subjects:	[18F] Afatinib NSCLC EGFR TKI PET/CT Targeted therapy Lung cancer
Online Access:	http://link.springer.com/article/10.1186/s13550-020-00684-4

Similar Items

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
by: Eveline Van De Stadt, et al.
Published: (2022-10-01)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
by: I. H. Bartelink, et al.
Published: (2022-06-01)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
by: Chiao-En Wu, et al.
Published: (2021-07-01)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
by: Xiaoxi Zhu, et al.
Published: (2021-11-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
by: Jing Liu, et al.
Published: (2019-07-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients
by: Eveline Annette van de Stadt, et al.
Published: (2022-04-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
by: Junyan Tao, et al.
Published: (2020-09-01)

A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review
by: Yu Wei, et al.
Published: (2021-06-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01)

TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS
by: T. Y. SEMIGLAZOVA, et al.
Published: (2016-12-01)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
by: German E. Ramos, et al.
Published: (2022-11-01)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
by: Liping Kang, et al.
Published: (2023-02-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
by: Yang Wei, MD, et al.
Published: (2021-07-01)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
by: Chih-Hsi Scott Kuo, et al.
Published: (2022-01-01)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
by: Arnold A, et al.
Published: (2023-07-01)

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations
by: Giuseppe Pompilio, et al.
Published: (2022-01-01)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
by: Keunchil Park, et al.
Published: (2021-07-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
by: Xu Z, et al.
Published: (2022-06-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
by: Alex Friedlaender, et al.
Published: (2021-03-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
by: Xue C, et al.
Published: (2016-03-01)

Association Between Single Nucleotide Polymorphisms in ESR Pathway and Risk of Brain Metastasis in NSCLC with EGFR Mutation
by: WU Bili, et al.
Published: (2020-10-01)

Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma
by: Blandine Jelli, et al.
Published: (2021-08-01)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
by: Nobuaki Kobayashi, et al.
Published: (2020-08-01)